- **EUDA Health Holdings Ltd. reported a significant increase in total revenue by 60.2% to $3,057,323 for the six months ended June 30, 2025, compared to $1,908,048 for the same period in 2024, while also reducing its net loss by 92.9% to $(1,201,696) from $(16,832,947) in the prior year period**.  **[1847846_0001493152-25-016547_ex99-2.htm:0]** 
- **The company's management has determined there is substantial doubt about its ability to continue as a going concern within one year due to recurring losses from operations and negative cash flows, and is actively seeking additional financing**.  **[1847846_0001493152-25-016547_ex99-2.htm:6]** 
- **A new revenue stream from holistic wellness consumer products and services, totaling $893,785 for the six months ended June 30, 2025, was introduced following the acquisition of Fortress Cove in May 2024**.  **[1847846_0001493152-25-016547_ex99-2.htm:2]** **[1847846_0001493152-25-016547_ex99-1.htm:24]** 
- **EUDA successfully had a statutory demand for US$138,202.66 in alleged legal fees set aside by the British Virgin Islands Court on May 1, 2025**.  **[1847846_0001493152-25-016547_ex99-1.htm:38]**

EUDA Health Holdings Ltd. Reports Half-Year 2025 Financial Results and Going Concern Uncertainty

- **EUDA Health Holdings Limited** signed a **Letter of Intent (LOI)** on **August 28, 2025**, to potentially acquire **Chemokine Pte Ltd**.  **[1847846_0001493152-25-012444_ex99-1.htm:1]** 
- The LOI grants EUDA an **exclusivity period of at least 120 days** to conduct due diligence on Chemokine, during which Chemokine will not engage in similar discussions with other entities.  **[1847846_0001493152-25-012444_ex99-1.htm:1]** 
- Chemokine is a Singapore-based biotech company focused on molecular supplements and gene modulating formulations, including **Euda Helixé**, a next-generation immune health supplement for which EUDA already holds exclusive worldwide distribution rights.  **[1847846_0001493152-25-012444_ex99-1.htm:1]**

EUDA Health Holdings (EUDA)